作者: M T Huizing , G Giaccone , L J van Warmerdam , H Rosing , P J Bakker
DOI: 10.1200/JCO.1997.15.1.317
关键词:
摘要: PURPOSETo investigate the pharmacokinetics and pharmacodynamics of paclitaxel (P) carboplatin (C) in a sequence-finding dose-escalating study untreated non-small-cell lung cancer (NSCLC) patients.PATIENTS AND METHODSFifty-five chemotherapy-naive patients with NSCLC were entered onto pharmacokinetic part large phase I trial which P was administered as 3-hour infusion at dosages 100 to 250 mg/m2, C over 30 minutes 300 400 mg/m2. Patients randomized for sequence administration, first followed by or vice versa. Each patient received alternate during second subsequent courses.RESULTSThe most important hematologic toxicity encountered-was neutropenia. Hematologic not dependent on administered, but there cumulative Nonhematologic toxicities consisted mainly vomiting, myalgia, arthralgia. No sequence-dependent interactions area unde...